Oxford BioTherapeutics in £244 million cancer antibody deal with GSK
This article was originally published in Scrip
Executive Summary
Oxford BioTherapeutics (OBT) has entered into a major alliance with GlaxoSmithKline worth up to £244 million in fees and milestones to discover, develop and commercialise therapeutic antibodies in oncology.